Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of (18)F-FDG PET, (11)C-methionine PET and perfusion MRI

Purpose: The authors analyzed the characteristics of perfusion magnetic resonance imaging (MRI), (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and (11)C-methionine (MET) PET to compare the efficacies of these modalities in making the distinction between radiation necrosis and tumor recurrence of high-grade glioma. Patients and methods: Ten patients were evaluated with dynamic susceptibility contrast perfusion MRI, (11)C-MET PET and (18)F-FDG PET to visualize gadolinium-enhanced lesions during the post-radiation follow-up period. In the perfusion MRI, four regions of interest (ROIs) were identified and average values were calculated. A reference ROI of the same size was defined in the contralateral white matter to obtain the relative cerebral blood volume (rCBV). After coregistering the PET images with the MRI, we measured the maximum uptake values of the lesion and of the contralateral cerebral white matter as reference area to calculate the L(max)/R(max) ratio. Results: The rCBV was higher in the recurrence group than in the necrosis group (p = 0.010). There was no difference between groups in terms of the L(max)/R(max) ratio as derived from the 18F-FDG and (11)C-MET PET. Conclusion:A quantitative rCBV as calculated from a perfusion MRI scan might be superior to the L(max)/R(max) ratio as derived from (18)F-FDG and (11)C-MET PET in order to distinguish a recurrence of high-grade glioma from radiation necrosis. (C) 2010 Elsevier B.V. All rights reserved.Arvinda HR, 2009, J NEURO-ONCOL, V94, P87, DOI 10.1007/s11060-009-9807-6Peca C, 2009, CLIN NEUROL NEUROSUR, V111, P331, DOI 10.1016/j.clineuro.2008.11.003Hu LS, 2009, AM J NEURORADIOL, V30, P552, DOI 10.3174/ajnr.A1377Young GS, 2009, AM J NEURORADIOL, V30, P575, DOI 10.3174/ajnr.A1239Barajas RF, 2009, AM J NEURORADIOL, V30, P367, DOI 10.3174/ajnr.A1362Tie J, 2008, J CLIN NEUROSCI, V15, P1327, DOI 10.1016/j.jocn.2007.12.008Hatakeyama T, 2008, EUR J NUCL MED MOL I, V35, P2009, DOI 10.1007/s00259-008-0847-5Kato T, 2008, AM J NEURORADIOL, V29, P1176, DOI 10.3174/ajnr.A1008Brandsma D, 2008, LANCET ONCOL, V9, P453Terakawa Y, 2008, J NUCL MED, V49, P694, DOI 10.2967/jnumed.107.048082Di Costanzo A, 2008, RADIOL MED, V113, P134, DOI 10.1007/s11547-008-0232-2Chen W, 2007, J CLIN ONCOL, V25, P4714, DOI 10.1200/JCO.2006.10.5825Zeng QS, 2007, INT J RADIAT ONCOL, V68, P151, DOI 10.1016/j.ijrobp.2006.12.001Sundgren PC, 2006, MAGN RESON IMAGING, V24, P1131, DOI 10.1016/j.mri.2006.07.008Borbely K, 2006, J NEUROL SCI, V246, P85, DOI 10.1016/j.jns.2006.02.015Rachinger W, 2005, NEUROSURGERY, V57, P505, DOI 10.1227/01.NEU.0000171642.49553.B0Stupp R, 2005, NEW ENGL J MED, V352, P987Van Laere K, 2005, EUR J NUCL MED MOL I, V32, P39, DOI 10.1007/s00259-004-1564-3Hustinx R, 2005, RADIOL CLIN N AM, V43, P35, DOI 10.1016/j.rcl.2004.09.009Kim S, 2005, EUR J NUCL MED MOL I, V32, P52, DOI 10.1007/s00259-004-1598-6Spaeth N, 2004, J NUCL MED, V45, P1931Downey RJ, 2004, J CLIN ONCOL, V22, P3255, DOI 10.1200/JCO.2004.11.109Giammarile F, 2004, J NEURO-ONCOL, V68, P263Tsuyuguchi N, 2004, ANN NUCL MED, V18, P291Hein PA, 2004, AM J NEURORADIOL, V25, P201Chan YL, 2003, J COMPUT ASSIST TOMO, V27, P674Ichinose T, 2003, NEUROL MED-CHIR, V43, P461Wong TZ, 2002, NEUROIMAG CLIN N AM, V12, P615Schlemmer HP, 2002, NEURORADIOLOGY, V44, P216, DOI 10.1007/s002340100703Chao ST, 2001, INT J CANCER, V96, P191Meyer PT, 2001, EUR J NUCL MED, V28, P165Kumar AJ, 2000, RADIOLOGY, V217, P377Langleben DD, 2000, J NUCL MED, V41, P1861Fuss M, 2000, INT J RADIAT ONCOL, V48, P53Sugahara T, 2000, AM J NEURORADIOL, V21, P901Knopp EA, 1999, RADIOLOGY, V211, P791Sugahara T, 1998, AM J ROENTGENOL, V171, P1479Ricci PE, 1998, AM J NEURORADIOL, V19, P407Hazle JD, 1997, JMRI-J MAGN RESON IM, V7, P1084ROELCKE U, 1995, J NEUROL SCI, V132, P20FORSYTH PA, 1995, J NEUROSURG, V82, P436KAHN D, 1994, AM J ROENTGENOL, V163, P1459ARONEN HJ, 1994, RADIOLOGY, V191, P41CHIANG CS, 1993, RADIOTHER ONCOL, V29, P60MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277PAULUS W, 1989, CANCER, V64, P442PATRONAS NJ, 1982, RADIOLOGY, V144, P885WALKER MD, 1978, J NEUROSURG, V49, P333

Development and Characterization of Tissue Equivalent Proportional Counter for Radiation Monitoring in International Space Station

Tissue equivalent proportional counter (TEPC) can measure the Linear Energy Transfer (LET) spectrum and calculate the equivalent dose for the complicated radiation field in space. In this paper, we developed and characterized a TEPC for radiation monitoring in International Space Station (ISS). The prototype TEPC which can simulate a 2 μm of the site diameter for micro-dosimetry has been tested with a standard alpha source (241Am, 5.5 MeV). Also, the calibration of the TEPC was performed by the 252Cf neutron standard source in Korea Research Institute of Standards and Science (KRISS). The determined calibration factor was kf = 3.59×10-7 mSv/R